ASX:GSS Genetic Signatures (GSS) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free GSS Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Genetic Signatures alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Genetic Signatures Stock (ASX:GSS)Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… GSS Stock News HeadlinesMarch 6, 2024 | msn.comGenetic mutation in a quarter of all Labradors hard-wires them for obesityFebruary 6, 2024 | msn.comResearchers at U of C reveal new kit making genetic mutation testing quick, accessible, affordableApril 24, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. February 6, 2024 | msn.comResearchers create a new tool to rapidly diagnose genetic mutationsJanuary 13, 2024 | money.usnews.comGenetic Counselor SalaryJanuary 5, 2024 | morningstar.comGenetic Signatures Ltd GSSDecember 13, 2023 | bbc.comHow ancient DNA is transforming our view of the pastNovember 13, 2023 | bbc.co.ukHow is genetic information inherited? - OCR 21st CenturyApril 24, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. October 16, 2023 | msn.comGenetic science is the future of food security – Olam Agri Brands MgrSeptember 22, 2023 | finance.yahoo.comCalculating The Intrinsic Value Of Genetic Signatures Limited (ASX:GSS)September 4, 2023 | msn.comASX Health Stocks: Genetic Signatures jumps 20pc on FDA update, Proteomics reveals new patent in JapanAugust 14, 2023 | cbsnews.comGenetic genealogist helps solve a case that had "a gnat's eyebrow of DNA" left from the crime sceneJune 13, 2023 | abcnews.go.comLawyer arrested in over decade-old rapes after being identified by genetic genealogyMay 3, 2023 | nj.comHow DNA and genetic genealogy are solving decades-old cold cases | The Unidentifieds podcast: Ep. 3April 15, 2023 | msn.comGenetic signature discovery may revolutionise liver cancer diagnosis and monitoringApril 12, 2023 | omaha.comGermline Genetic Testing Feasible for Advanced Prostate CancerApril 6, 2023 | bbc.co.ukPotential benefits and risks of genetic engineeringMarch 31, 2023 | nytimes.comDNA Confirms Oral History of Swahili PeopleMarch 15, 2023 | msn.comMoneyTalks: Zip share price could quadruple while Genetic Signatures to triple, say these brokersMarch 3, 2023 | msn.comUnknown lineage of ice age Europeans discovered in genetic studyJanuary 18, 2023 | uk.news.yahoo.comThose who invested in Genetic Signatures (ASX:GSS) five years ago are up 210%January 11, 2023 | foxnews.comMassachusetts woman murdered more than 50 years ago identified by authorities using genetic genealogyDecember 11, 2022 | marketwatch.comGenome Editing Market Dynamics with Top Players, Gross Margin, Regional Demand, Plans and Demand Status Forecast to 2028November 3, 2022 | cnbc.comThese dads drove over 57 hours, livestreamed the cross-country trip on YouTube and raised $156,000 for their kids’ rare genetic diseaseOctober 12, 2022 | nz.finance.yahoo.comAre Genetic Signatures Limited's (ASX:GSS) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?September 2, 2022 | investing.comGenetic Signatures Ltd (GSS)See More Headlines Receive GSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genetic Signatures and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolASX:GSS CUSIPN/A CIKN/A Webwww.geneticsignatures.com Phone61 2 9870 7580FaxN/AEmployees1,626Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,040,000.00 Net Margins-112.83% Pretax MarginN/A Return on Equity-40.28% Return on Assets-23.50% Debt Debt-to-Equity Ratio0.03 Current Ratio8.06 Quick Ratio8.54 Sales & Book Value Annual Sales$15.99 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.28 per share Price / BookN/AMiscellaneous Outstanding Shares186,480,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.12 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. John R. Melki BScPh.D., MD, CEO & Executive DirectorMr. Michael Anton Aicher BSc (Age 64)M.B.A., MBA, Executive Director of US Operations & Executive Director Comp: $178.42kMr. Christopher M. AbbottFounder & Chairman EmeritusMr. Karl David PechmannCFO, COO & Company SecretaryDr. Douglas S. Millar BScPh.D., Chief Scientific OfficerMs. Rebecca AbbatantuonoGlobal Head of People & CultureMs. Neralie Coulston B.Sc.Global Head of Regulatory AffairsMr. Jackson Jones B.Sc.Chief Commercial OfficerMore ExecutivesKey CompetitorsANGLEOTCMKTS:ANPCYAustralian Clinical LabsASX:ACLBARD1 Life SciencesASX:BD1BCAL DiagnosticsASX:BDXbioAffinity TechnologiesNASDAQ:BIAFWView All CompetitorsInsidersStephane ChatonskyBought 112,733 shares on 2/27/2024Total: $58,621.16 ($0.52/share)Caroline WaldronSold 2,512 sharesTotal: $929.44 ($0.37/share)Caroline WaldronSold 250,000 sharesTotal: $108,750.00 ($0.44/share) This page (ASX:GSS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss RatingsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genetic Signatures Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
